{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:01:29Z","timestamp":1790744489592,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective: <\/jats:bold>We aimed to determine the burden of opioid consumption in a cohort of patients with functional gastrointestinal disorders.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold>All patients diagnosed with functional gastrointestinal disorders and referred to our university hospital were evaluated from 2013 to the beginning of 2019. Irritable bowel syndrome and functional dyspepsia diagnoses were determined according to Rome criteria and severity according to irritable bowel syndrome severity scoring system. Vomiting was quantified using a 5-point Likert scale, and constipation severity was measured using the Knowles-Eccersley-Scott-Symptom questionnaires. Quality of life was quantified by the GastroIntestinal Quality of Life Index. Patients were categorized as being treated on a chronic basis with either tramadol, step II opioids, step III opioids or as being opioid-free.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold>2933 consecutive patients were included. In our cohort, 12.5% had only irritable bowel syndrome, 39.3% had only functional dyspepsia, 24.9% had a combination of both, and 23.4% had other functional gastrointestinal disorders. Among them, the consumption of tramadol, step II (tramadol excluded) and step III opioids was 1.8, 1.3 and 0.3 % respectively in 2013 and 4.3, 3.4 and 1.9% in 2018 (<jats:italic>p<\/jats:italic> &amp;lt; 0.03). Opioid consumption was associated with increased vomiting (<jats:italic>p<\/jats:italic> = 0.0168), constipation (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001), symptom severity (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), more altered quality of life (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001) and higher depression score (<jats:italic>p<\/jats:italic> = 0.0045).<\/jats:p><jats:p><jats:bold>Conclusion: <\/jats:bold>In functional gastrointestinal disorders, opioid consumption has increased in the last years and is associated with more GI symptoms (vomiting, constipation and GI severity), higher depression and more altered quality of life.<\/jats:p>","DOI":"10.3389\/fphar.2020.596467","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T13:29:22Z","timestamp":1608730162000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Impact of Opioid Consumption in Patients With Functional Gastrointestinal Disorders"],"prefix":"10.3389","volume":"11","author":[{"given":"Chlo\u00e9","family":"Melchior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Desprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Wuestenberghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Leroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Lemaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Goucerol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/jgh.13642","article-title":"Comparison of the Rome IV and Rome III criteria for IBS diagnosis: a cross-sectional survey","volume":"32","author":"Bai","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ejp.1337","article-title":"Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990-2016","volume":"23","author":"Bosetti","year":"2019","journal-title":"Eur. J. Pain"},{"key":"B3","doi-asserted-by":"publisher","first-page":"776.e2","DOI":"10.1053\/j.gastro.2019.10.017","article-title":"Opioid prescription patterns among US gastroenterologists from 2013 to 2017","volume":"158","author":"Chen","year":"2020","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ejp.1291","article-title":"Prescription opioid analgesic use in France: trends and impact on morbidity-mortality","volume":"23","author":"Chenaf","year":"2019","journal-title":"Eur. J. Pain"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/j.1365-2036.2008.03689.x","article-title":"Gastrointestinal side effects in chronic opioid users: results from a population-based survey","volume":"27","author":"Cook","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"F1000 Faculty Rev-257","DOI":"10.12688\/f1000research.15974.1","article-title":"Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders?","volume":"8","author":"Corsetti","year":"2019","journal-title":"F1000Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1097\/MIB.0000000000000194","article-title":"Narcotic use and misuse in Crohn's disease","volume":"20","author":"Crocker","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cpdd.378","article-title":"Safety, tolerability, and pharmacokinetics of therapeutic and supratherapeutic doses of tramadol hydrochloride in healthy adults: a randomized, double-blind, placebo-controlled multiple-ascending-dose study","volume":"6","author":"DeLemos","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"CD012509","DOI":"10.1002\/14651858.CD012509.pub2","article-title":"Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of cochrane reviews","volume":"10","author":"Els","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2050640618818305","article-title":"Pathophysiology and management of opioid-induced constipation: European expert consensus statement","volume":"7","author":"Farmer","year":"2019","journal-title":"United European Gastroenterol J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1503\/cmaj.051528","article-title":"Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects","volume":"174","author":"Furlan","year":"2006","journal-title":"CMAJ (Can. Med. Assoc. J.)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e13298","DOI":"10.1111\/nmo.13298","article-title":"Effects of naloxegol on whole gut transit in opioid-na\u00efve healthy subjects receiving codeine: a randomized, controlled trial","volume":"30","author":"Halawi","year":"2018","journal-title":"Neuro Gastroenterol. Motil."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/bcp.13564","article-title":"Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe","volume":"84","author":"Hider-Mlynarz","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"118048","DOI":"10.1016\/j.lfs.2020.118048","article-title":"Preventive effects of naldemedine, peripherally acting \u03bc-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets","volume":"257","author":"Kanemasa","year":"2020","journal-title":"Life Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/BF02236639","article-title":"Linear discriminant analysis of symptoms in patients with chronic constipation: validation of a new scoring system (KESS)","volume":"43","author":"Knowles","year":"2004","journal-title":"Dis. Colon Rectum"},{"key":"B17","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ibd.21806","article-title":"Narcotic use for inflammatory bowel disease and risk factors during hospitalization","volume":"18","author":"Long","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e13290","DOI":"10.1111\/nmo.13290","article-title":"Are characteristics of abdominal pain helpful to identify patients with visceral hypersensitivity in irritable bowel syndrome? Results of a prospective study","volume":"30","author":"Melchior","year":"2018","journal-title":"Neuro Gastroenterol. Motil."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00228-018-2536-z","article-title":"Vomiting and constipation associated with tramadol and codeine: a comparative study in VigiBase\u00ae","volume":"74","author":"Montastruc","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.14309\/ajg.0000000000000614","article-title":"Chronic constipation in the United States: results from a population-based survey assessing healthcare seeking and use of pharmacotherapy","volume":"115","author":"Oh","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jpeds.2018.03.037","article-title":"Prevalence of functional gastrointestinal disorders in children and adolescents: comparison between Rome III and Rome IV criteria","volume":"199","author":"Saps","year":"2018","journal-title":"J. Pediatr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00520-019-04884-0","article-title":"A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting","volume":"28","author":"Sato","year":"2020","journal-title":"Support Care Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/apt.14503","article-title":"Opioid medication use in patients with gastrointestinal diagnoses vs unexplained gastrointestinal symptoms in the US veterans health administration","volume":"47","author":"Sayuk","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1177\/0300060519869515","article-title":"Effect of fentanyl on nausea and vomiting in cesarean section under spinal anesthesia: a randomized controlled study","volume":"47","author":"Shin","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"B27","first-page":"25","article-title":"[First validation of the French version of the gastrointestinal quality of life index (GIQLI)]","volume":"23","author":"Slim","year":"1999","journal-title":"Gastroenterol. Clin. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrgastro.2017.141","article-title":"Opioid misuse in gastroenterology and non-opioid management of abdominal pain","volume":"15","author":"Szigethy","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/00325481.2016.1128306","article-title":"Why oral opioids may not be effective in a subset of chronic pain patients","volume":"128","author":"Tennant","year":"2015","journal-title":"Postgrad. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1634\/theoncologist.2017-0225","article-title":"Efficacy of prophylactic treatment for oxycodone-induced nausea and vomiting among patients with cancer pain (point): a randomized, placebo-controlled, double-blind trial","volume":"23","author":"Tsukuura","year":"2017","journal-title":"Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11916-018-0670-z","article-title":"The opioid crisis: a comprehensive overview","volume":"22","author":"Vadivelu","year":"2018","journal-title":"Curr. Pain Headache Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s10620-018-5343-6","article-title":"Overlap of irritable bowel syndrome and functional dyspepsia in the clinical setting: prevalence and risk factors","volume":"64","author":"von Wulffen","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"updated-by":[{"DOI":"10.3389\/fphar.2021.652927","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.596467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T13:29:23Z","timestamp":1608730163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.596467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,21]]},"references-count":33,"alternative-id":["10.3389\/fphar.2020.596467"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.596467","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fphar.2021.652927","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,21]]},"article-number":"596467"}}